Trial Profile
A randomized placebo-controlled, Phase 1b pharmacokinetic/pharmacodynamic trial of AM-201 co-administration with olanzapine in Antipsychotic-Induced Weight Gain.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Betahistine (Primary) ; Olanzapine
- Indications Somnolence; Weight gain
- Focus Proof of concept; Therapeutic Use
- Sponsors Altamira Therapeutics; Auris Medical
- 26 May 2020 According to an Auris Medical media release, the company to disclose detailed results from the study in a scientific journal.
- 26 May 2020 Primary endpoint (Reduction in weight gain at 30mg) has been met, according to an Auris Medical media release.
- 26 May 2020 Positive top-line results presented in an Auris Medical Media Release.